At Vision Expo, the company behind the Heru Prime virtual reality headset for vision care pretesting showcased an upgrade ...

The primary applications of virtual reality in ophthalmology include physician and patient education, diagnostic testing in ...

Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...

Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

ABSTRACT: Objective: To determine the demographic characteristics, incidence trends, and treatment outcomes of Pediatric Traumatic Brain Injury at Bugando Medical Center (BMC). Methods: A ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch to head its commercial team. David Robinson has joined Ocular as global ...

Purpose To identify factors associated with visual function and quality of life (QOL) in cosmetic shell (scleral shell) wearers. Methods This nationwide, cross-sectional, multicentre study was ...

Ocular Therapeutix (OCUL) added ~21% in the premarket on Thursday after the French publication La Lettre reported that Sanofi (SNY) is readying an improved takeover offer to acquire the U.S. eye ...

Sanofi is readying an improved takeover offer for Ocular Therapeutix after the company rejected a prior proposal, according to several outlets, citing a report from French publication La Lettre. The ...